Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer

Abstract

Abstract Advanced cancer is frequently associated with a significant anemia that may be due to the disease itself or the effect of concomitantly administered chemotherapeutic agents. In a series of double-blind, placebo-controlled trials, three populations of anemic cancer patients were randomized to rHuEPO or placebo. The three populations were: A) patients not receiving concomitant chemotherapy, B) patients receiving chemotherapeutic regimens which did not contain cisplatin, and C) patients receiving chemotherapeutic regimens which contained cisplatin. In the no-chemotherapy trials, patients were treated with rHuEPO (100 U/kg) or placebo s.c. three times a week for up to eight weeks. In the two types of chemotherapy trials, patients were treated with rHuEPO (150 U/kg) or placebo SC three times a week for 12 weeks. A total of 413 patients were enrolled in these trials (124 in the no-chemotherapy group, 157 in the no-cisplatin chemotherapy group and 132 in the cisplatin chemotherapy group). In each trial, patients randomized to rHuEPO had a significantly greater (p < .004) increase in hematocrit than placebo-treated patients. In the two types of chemotherapy trials combined, utilizing an rHuEPO dose of 150 U/kg, rHuEPO-treated patients had significantly lower (p ≤ .009) transfusion requirements (percentage of patients transfused and mean units of blood transfused per patient) than placebo-treated patients during months two and three, but not during month one. Quality-of-life parameters measured on a 100 mm visual analog scale significantly improved (p<.05) in rHuEPO-treated patients whose hematocrit increased ≥6 percentage points, compared to corresponding quality-of-life changes in placebo-treated patients. rHuEPO was well tolerated compared to placebo. The above results suggest that rHuEPO may be a useful agent to palliate the morbid consequences of the anemia that is often found in association with advanced cancer.